![Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes | Business Wire Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes | Business Wire](https://mms.businesswire.com/media/20211027005515/en/739014/23/teva_RGB_JPEG.jpg)
Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes | Business Wire
![Polpharma Biologics Group Announces That Its Joint Venture Company, Bioeq, Has Entered Into a Commercialization Agreement for Biosimilar Ranibizumab | Business Wire Polpharma Biologics Group Announces That Its Joint Venture Company, Bioeq, Has Entered Into a Commercialization Agreement for Biosimilar Ranibizumab | Business Wire](https://mms.businesswire.com/media/20210707005415/en/889874/23/Logotype-Polpharma_Biologics_%282%29.jpg)
Polpharma Biologics Group Announces That Its Joint Venture Company, Bioeq, Has Entered Into a Commercialization Agreement for Biosimilar Ranibizumab | Business Wire
Opioid prescribing in out-of-hours primary care in Flanders and the Netherlands: A retrospective cross-sectional study | PLOS ONE
Teva Announces Pricing of $15 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Generics Jerusalem, July
![Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder](https://mms.businesswire.com/media/20200921005170/en/819864/4/Interactive_Media_Placeholder_webready.jpg)